Sprint PNS Now Covered by Aetna, What It Means for Chronic Pain Patients

In March 2026, Aetna updated its clinical policy. It now covers Sprint Peripheral Nerve Stimulation (PNS) for specific chronic pain conditions. This therapy is temporary and does not need a permanent implant. This is a meaningful development for patients who have tried physical therapy, medications, and injections without lasting relief. The post on osteopathic medicine and the chronic pain crisis explains why so many patients exhaust conservative care without resolution.

Dr. Knopp has been performing Sprint PNS at Hartford HealthCare's Pain Treatment Center. The new Aetna coverage significantly expands who can access it. Here is what you need to know.

What Is Sprint PNS?

Sprint Peripheral Nerve Stimulation is a short-term (60-day) neuromodulation therapy. A thin wire electrode is placed near the affected peripheral nerve under ultrasound guidance. No surgery and no permanent implant are needed. A small external pulse generator worn on the body delivers mild electrical signals that interrupt pain transmission. You can find a full overview of the procedures Dr. Knopp offers for chronic pain, including Sprint PNS.

After 60 days, the electrode is removed in a brief office procedure. No hardware remains in the body.

This is categorically different from spinal cord stimulation (SCS), which involves a permanent implant near the spinal cord. Sprint PNS targets peripheral nerves, the nerves outside the spine. This makes it appropriate for localized pain that has not responded to conservative treatment.

What the Evidence Shows

The evidence base for Sprint PNS is substantial. A multicenter study published in Pain Physician evaluated 6,160 patients. They were treated with peripheral nerve stimulation for shoulder, knee, lower back, and foot/ankle pain. The patients had chronic pain and had already tried and failed multiple treatments:

• 71% achieved ≥50% pain reduction, the standard threshold for clinical success
• Among responders, the average pain relief was 63%
• Average pain scores fell markedly by the 60-day follow-up
• Functional improvement was maintained at follow-up in the majority of responders

These numbers matter because of the patient population studied. It was not a cherry-picked trial group. It included people with complex, treatment-resistant pain who had previously tried injections, physical therapy, and medications.

What Conditions Qualify Under the New Aetna Policy?

Aetna's March 2026 policy covers Sprint PNS for intractable neuropathic pain. This is chronic pain that has not responded to other treatment. Coverage depends on the nature of the pain (peripheral, neuropathic, treatment-resistant). It is not based on a checklist of body parts.

In practice, this applies to specific peripheral nerve pain in areas where Sprint PNS is most used and studied:

• Shoulder pain (including rotator cuff-related and post-surgical pain)
• Knee pain (including post-arthroplasty and osteoarthritic pain)
• Low back pain with a peripheral nerve component
• Foot and ankle pain that has failed conservative management

Aetna's criteria include chronic intractable pain that is refractory to conservative care. This care must include in-person physical therapy for at least 6 weeks in the past year, medications, and injection or surgical options. There must be no active drug addiction and no psychological contraindication. Sprint PNS is a temporary 60-day therapy, not a permanent implant. So Aetna's policy does not require a separate stimulation trial beforehand.

The policy does not cover Sprint PNS for diffuse pain syndromes, fibromyalgia, or central sensitization conditions. It is designed for anatomically specific, peripheral nerve-mediated pain.

How Dr. Knopp Determines Who Is a Candidate

Before recommending Sprint PNS, Dr. Knopp evaluates several factors:

• Pain localization. Is the pain specific enough to target a single peripheral nerve? A patient with diffuse back pain from a multi-level disc problem may not be an ideal candidate. A patient with well-localized shoulder pain from a suprascapular nerve distribution often is.
• Treatment history. Sprint PNS is not a first-line treatment. At least 3-6 months of documented conservative care is standard. This includes physical therapy and at least one image-guided injection.
• Diagnostic nerve block response. In most cases, Dr. Knopp will perform a diagnostic block of the target nerve first. A ≥50% temporary reduction in pain from the block is a strong predictor of Sprint PNS success.
• Functional goals. The conversation focuses on what the patient wants to do again: return to work, sleep through the night, resume activity. It is not just about a target pain score.

What the 60-Day Treatment Looks Like

The procedure is performed at Hartford HealthCare's Pain Treatment Center in West Hartford. Here is the general sequence:

1. Placement (Day 1): A thin electrode wire is placed near the target nerve through a small introducer needle. Ultrasound and/or fluoroscopic guidance is used. The procedure takes 20-45 minutes. Most patients go home the same day.
2. Stimulation (Days 1-60): A small external pulse generator (worn on the body, roughly the size of a credit card) is connected to the electrode lead. Parameters are programmed and adjusted at follow-up visits. Most patients feel a mild buzzing or tingling rather than pain.
3. Removal (Day 60): The electrode is removed in a brief office procedure. No incision is needed. The wire is simply extracted.

Patients continue normal activity during the treatment period with minor restrictions (no submersion in water, no high-impact activity at the insertion site).

How Sprint PNS Differs from Permanent Spinal Cord Stimulation

This is one of the most common questions Dr. Knopp hears. The short answer: Sprint PNS is a diagnostic and therapeutic tool. SCS is a long-term commitment.

Sprint PNS is often used as a bridge or trial before deciding on a permanent implant. If 60 days of peripheral nerve stimulation provides significant relief, it supports the case that neuromodulation is the right pathway. It helps guide the decision about whether a permanent device makes sense.

It also serves as a standalone treatment. Many patients achieve lasting relief after the 60-day course without needing anything further. The mechanism is thought to involve both direct pain signal interruption and longer-term neuroplastic changes. The nerve "relearns" normal signaling after weeks of modulated input. For patients who are not Sprint PNS candidates, regenerative options like PRP may offer a non-surgical path forward. Patients considering injections for joint or tendon pain should also review the post on PRP versus cortisone, which covers why repeated steroid injections can make degenerative conditions worse over time.

How to Find Out If You Qualify

The first step is an evaluation at Dr. Knopp's West Hartford office. During that visit, he will review your imaging and treatment history. He will also do a hands-on exam to determine whether Sprint PNS is appropriate and whether the initial step should be a diagnostic nerve block first.

Sprint PNS is performed at Hartford HealthCare, so the hospital bills it through your insurance and handles any pre-authorization. If you have Aetna and meet the coverage criteria, that authorization is typically obtained before the placement procedure. Dr. Knopp's own West Hartford concierge practice does not bill insurance. The evaluation that determines whether you are a candidate is private-pay.